ScholarIQanswers from OpenAlex & ORCID
Vanita Noronha
ResearcherPublications, citations & collaboration network
Vanita Noronha is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Vanita Noronha have?
ScholarIQindexed works
Vanita Noronha has 652 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Vanita Noronha have?
ScholarIQcitation count
Vanita Noronha has 7,735 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Vanita Noronha?
ScholarIQh-index
Vanita Noronha has an h-index of 38 in OpenAlex.
What is the i10-index of Vanita Noronha?
ScholarIQi10-index
Vanita Noronha has an i10-index of 140 in OpenAlex.
What is the ORCID of Vanita Noronha?
ScholarIQorcid
The ORCID for Vanita Noronha is on the source record.
What is the OpenAlex record for Vanita Noronha?
ScholarIQopenalex
The OpenAlex for Vanita Noronha is on the source record.
What are the most-cited papers on Vanita Noronha?
ScholarIQmost cited works
Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update
William Dale, Heidi D. Klepin, Grant R. Williams, Shabbir M.H. Alibhai, Cristiane Decat Bergerot, Karlynn BrintzenhofeSzoc, Judith O. Hopkins, Minaxi Jhawer, Vani Katheria, Kah Poh Loh, Lisa M. Lowenstein, June M. McKoy, Vanita Noronha, Tanyanika Phillips, Ashley Rosko, Tracy Ruegg, Melody K. Schiaffino, John F. Simmons, Ishwaria M. Subbiah, William P. Tew, Tracy L. Webb, Mary Whitehead, Mark R. Somerfield, Supriya G. Mohile
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in <i>EGFR</i>-Mutated Lung Cancer
Vanita Noronha, Vijay Patil, Amit Joshi, Nandini Menon, Anuradha Chougule, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Rajiv Kumar, Sucheta More, Supriya Goud, Nandkumar Kadam, Nilesh Daware, Atanu Bhattacharjee, Srushti Shah, Akanksha Yadav, Vaishakhi Trivedi, Vichitra Behel, Amit Dutt, Shripad Banavali, Kumar Prabhash
Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial
Vanita Noronha, Amit Joshi, Vijay Patil, Jaiprakash Agarwal, Sarbani Ghosh Laskar, Ashwini Budrukkar, Vedang Murthy, Tejpal Gupta, Anil D′Cruz, Shripad Banavali, Prathamesh Pai, Pankaj Chaturvedi, Devendra Chaukar, Nikhil Pande, Arun Chandrasekharan, Vikas Talreja, Dilip Harindran Vallathol, Vijayalakshmi Mathrudev, Aparna Manjrekar, Kamesh Maske, Arati Sanjay Bhelekar, Kavita Nawale, Sadhana Kannan, Vikram Gota, Atanu Bhattacharjee, Shubhada Kane, Shashikant Juvekar, Kumar Prabhash
Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial
Vedang Murthy, Priyamvada Maitre, Sadhana Kannan, Gitanjali Panigrahi, Rahul Krishnatry, Ganesh Bakshi, Gagan Prakash, Mahendra Pal, Santosh Menon, Reena Phurailatpam, Smruti Mokal, Dipika Chaurasiya, Palak Popat, Nilesh Sable, Archi Agarwal, Venkatesh Rangarajan, Amit Joshi, Vanita Noronha, Kumar Prabhash, Umesh Mahantshetty
Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study
Vijay Patil, Vanita Noronha, Nandini Menon, Rahul Rai, Atanu Bhattacharjee, Ajay Singh, Kavita Nawale, Shweta Jogdhankar, Rupali Tambe, Sachin Dhumal, Riddhi Sawant, Mitali Alone, Devanshi Karla, Zoya Peelay, Shruti Pathak, Arun Balaji, Suman Kumar, Nilendu Purandare, Archi Agarwal, Ameya Puranik, Abhishek Mahajan, Amit Janu, Gunjesh Kumar Singh, Neha Mittal, Subhash Yadav, Shripad Banavali, Kumar Prabhash